Haemonetics Stock Price, News & Analysis (NYSE:HAE) $84.26 +3.39 (+4.19%) (As of 12/1/2023 ET) Add Compare Share Share Today's Range$80.48▼$84.6250-Day Range$80.65▼$92.6552-Week Range$72.26▼$95.26Volume367,798 shsAverage Volume253,277 shsMarket Capitalization$4.28 billionP/E Ratio33.84Dividend YieldN/APrice Target$103.40 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Haemonetics MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.50 Rating ScoreUpside/Downside22.7% Upside$103.40 Price TargetShort InterestBearish3.59% of Float Sold ShortDividend StrengthN/ASustainability-0.54Upright™ Environmental ScoreNews Sentiment0.45Based on 9 Articles This WeekInsider TradingSelling Shares$228,118 Sold Last QuarterProj. Earnings Growth6.68%From $3.89 to $4.15 Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.18 out of 5 starsMedical Sector420th out of 957 stocksSurgical & Medical Instruments Industry46th out of 92 stocks 2.3 Analyst's Opinion Consensus RatingHaemonetics has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 2 buy ratings, 2 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $103.40, Haemonetics has a forecasted upside of 22.7% from its current price of $84.26.Amount of Analyst CoverageHaemonetics has only been the subject of 2 research reports in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted3.59% of the float of Haemonetics has been sold short.Short Interest Ratio / Days to CoverHaemonetics has a short interest ratio ("days to cover") of 6.5.Change versus previous monthShort interest in Haemonetics has recently increased by 7.14%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldHaemonetics does not currently pay a dividend.Dividend GrowthHaemonetics does not have a long track record of dividend growth. Previous Next 4.3 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreHaemonetics has received a 64.94% net impact score from Upright. Haemonetics seems to create the most significant positive value in categories "Taxes", "Physical diseases", and "Relationships". The positive contribution in the "Physical diseases" impact category is mostly driven by its "Computerized clinical decision support software", "Hemofilters", and "Medical technology engineering" products. See details.Environmental SustainabilityThe Environmental Impact score for Haemonetics is -0.54. Previous Next 2.5 News and Social Media Coverage News SentimentHaemonetics has a news sentiment score of 0.45. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.76 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 9 news articles for Haemonetics this week, compared to 5 articles on an average week.Search Interest2 people have searched for HAE on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Haemonetics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Haemonetics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $228,118.00 in company stock.Percentage Held by InsidersOnly 1.79% of the stock of Haemonetics is held by insiders.Percentage Held by Institutions99.38% of the stock of Haemonetics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.9 Earnings and Valuation Earnings GrowthEarnings for Haemonetics are expected to grow by 6.68% in the coming year, from $3.89 to $4.15 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Haemonetics is 33.84, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 109.88.Price to Earnings Ratio vs. SectorThe P/E ratio of Haemonetics is 33.84, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 85.39.Price to Earnings Growth RatioHaemonetics has a PEG Ratio of 2.17. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioHaemonetics has a P/B Ratio of 4.78. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Haemonetics Stock (NYSE:HAE)Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and intravenous solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system, and Donor360. It also provides automated blood component and manual whole blood collection systems, such as MCS brand apheresis equipment to collect specific blood components from the donor; disposable whole blood collection and component storage sets; SafeTrace Tx blood bank information system; and BloodTrack blood management software, a suite of blood management and bedside transfusion solutions that combines software with hardware components, as well as an extension of the hospital's blood bank information system. In addition, the company offers hospital products comprising TEG, ClotPro, and HAS hemostasis analyzer systems that provide a comprehensive assessment of a patient's overall hemostasis; and TEG Manager software, which connects various TEG analyzers throughout the hospital, providing clinicians remote access to active and historical test results that inform treatment decisions. Further, it provides Cell Saver Elite +, an autologous blood recovery system for cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological surgeries; and VASCADE products comprising VASCADE and VASCADE MVP, a technology platform which offers catheter-based delivery system and leverages the natural clot including collagen. The company sells its products through direct sales force, independent distributors, and sales representatives. Haemonetics Corporation was founded in 1971 and is headquartered in Boston, Massachusetts.Read More HAE Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart HAE Stock News HeadlinesDecember 3, 2023 | americanbankingnews.comHaemonetics (NYSE:HAE) Raised to Strong-Buy at StockNews.comNovember 30, 2023 | finance.yahoo.comHaemonetics (HAE) Loses -6.71% in 4 Weeks, Here's Why a Trend Reversal May be Around the CornerDecember 3, 2023 | DTI Trader (Ad)New CBOE “special perk” helps traders target income every weekendYou might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange. November 29, 2023 | finance.yahoo.comCharles River (CRL) Backs the Quest to Cure SPG56 via New DealNovember 28, 2023 | finance.yahoo.comBruker's (BRKR) New Collaboration to Use MALDI Biotyper SystemNovember 28, 2023 | finance.yahoo.comPenumbra's (PEN) Expansion Moves, New Launches Aid GrowthNovember 28, 2023 | americanbankingnews.comContrasting PetVivo (NASDAQ:PETV) and Haemonetics (NYSE:HAE)November 27, 2023 | finance.yahoo.comHaemonetics' (HAE) Plasma Growth, Innovation Aid PerformanceDecember 3, 2023 | Wealthpress (Ad)Trading Experts Call It “The Perfect Tesla Trade”Thanks to a new discovery linked to shares of Tesla, regular folks can now target gains of 100% or more in six days or less. New research shows it’s happened 23 different times this year. The next trade is scheduled for this Thursday.November 27, 2023 | finance.yahoo.comHaemonetics (HAE) Stock Up 4.2% YTD: Will the Rally Continue?November 24, 2023 | finance.yahoo.comOrthofix (OFIX) Q3 Earnings Top Estimates, 2023 Sales View CutNovember 23, 2023 | finance.yahoo.comEssilorLuxottica (ESLOY), Moncler Ink Luxury Eyewear DealNovember 22, 2023 | seekingalpha.comHaemonetics: Solid Performance Of This Blood PlayNovember 21, 2023 | stocknews.com3 Medical Stocks to Buy for Future InvestmentsNovember 21, 2023 | finance.yahoo.comMedtronic (MDT) Q2 Earnings Beat Estimates, 2024 View UpNovember 21, 2023 | finance.yahoo.comBoston Scientific (BSX) Closes the Relievant Medsystems BuyoutNovember 20, 2023 | finance.yahoo.comParagon 28 (FNA) BEAST Cortical Fibers Launch Boosts BiologicsNovember 20, 2023 | finance.yahoo.comMedtronic's (MDT) Symplicity Spyral RDN System Gets FDA BoostNovember 20, 2023 | finance.yahoo.comMyriad Genetics (MYGN) Expands Pharma Services With New PactNovember 20, 2023 | finance.yahoo.comNational Vision's (EYE) Market Expansion Aids, Inflation AilsNovember 13, 2023 | finance.yahoo.comIDEXX's (IDXX) Upcoming Launch to Detect Canine LeishmaniosisNovember 10, 2023 | finance.yahoo.comIs Haemonetics (HAE) a Solid Growth Stock? 3 Reasons to Think "Yes"November 7, 2023 | finance.yahoo.comQIAGEN (QGEN) Launches Workflow to Boost Microbiome ResearchNovember 6, 2023 | markets.businessinsider.comHaemonetics (HAE): Promising Growth in Plasma Segment and International Expansion Fuels Buy Rating Despite Short-Term ConcernsNovember 5, 2023 | finance.yahoo.comHaemonetics Corporation (NYSE:HAE) Q2 2024 Earnings Call TranscriptNovember 3, 2023 | markets.businessinsider.comBuy Rating for Haemonetics: Consistent Performance, Financial Outperformance and Promising New ProductsNovember 3, 2023 | msn.comHaemonetics (HAE) Q2 Earnings Top Estimates, 2024 View UpSee More Headlines Receive HAE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Haemonetics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/02/2023Today12/03/2023Next Earnings (Estimated)2/06/2024Fiscal Year End3/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE Industry Surgical & medical instruments Sub-IndustryHealth Care Supplies SectorMedical Current SymbolNYSE:HAE CUSIP40502410 CIK313143 Webwww.haemonetics.com Phone(781) 848-7100Fax781-848-5106Employees3,034Year Founded1971Price Target and Rating Average Stock Price Target$103.40 High Stock Price Target$115.00 Low Stock Price Target$88.00 Potential Upside/Downside+22.7%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)$2.49 Trailing P/E Ratio33.84 Forward P/E Ratio21.66 P/E Growth2.17Net Income$115.40 million Net Margins10.35% Pretax Margin12.85% Return on Equity22.33% Return on Assets9.61% Debt Debt-to-Equity Ratio0.84 Current Ratio3.28 Quick Ratio2.19 Sales & Book Value Annual Sales$1.17 billion Price / Sales3.66 Cash Flow$4.97 per share Price / Cash Flow16.94 Book Value$17.61 per share Price / Book4.78Miscellaneous Outstanding Shares50,740,000Free Float49,834,000Market Cap$4.28 billion OptionableOptionable Beta0.34 Social Links 13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.Get This Free Report Key ExecutivesMr. Christopher A. Simon (Age 59)CEO, President & Director Comp: $3.26MMr. James C. D'Arecca CPA (Age 52)CFO, Executive VP & Financial Officer Comp: $1.8MMs. Anila Lingamneni (Age 55)Executive VP & CTO Comp: $1.09MMs. Michelle L. Basil (Age 51)Executive VP, General Counsel & Secretary Comp: $1.26MMr. Josep Lluis Llorens (Age 61)Executive Vice President of Global Manufacturing & Supply Chain Comp: $1.11MMs. Farris Maryanne Maunsell (Age 48)VP, Chief Accounting Officer & Principal Accounting Officer Ms. Olga GuyetteSenior Director of Investor RelationsCarla BurigattoVice President of CommunicationsMr. Rajeev VarmaSenior Vice President of Strategy & Corporate DevelopmentMs. Laurie A. Miller (Age 50)Senior VP & Chief Human Resources Officer More ExecutivesKey CompetitorsICU MedicalNASDAQ:ICUIInari MedicalNASDAQ:NARIIntegra LifeSciencesNASDAQ:IARTGlaukosNYSE:GKOSAxonicsNASDAQ:AXNXView All CompetitorsInsiders & InstitutionsWellington Management Group LLPSold 49,858 shares on 12/1/2023Ownership: 6.242%Comerica BankSold 5,916 shares on 11/21/2023Ownership: 0.042%Walleye Capital LLCBought 2,257 shares on 11/21/2023Ownership: 0.004%Shaolin Capital Management LLCSold 2,000,000 shares on 11/21/2023Ownership: 0.000%Wolverine Trading LLCBought 2,975 shares on 11/16/2023Ownership: 0.011%View All Insider TransactionsView All Institutional Transactions HAE Stock Analysis - Frequently Asked Questions Should I buy or sell Haemonetics stock right now? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Haemonetics in the last year. There are currently 2 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" HAE shares. View HAE analyst ratings or view top-rated stocks. What is Haemonetics' stock price target for 2024? 4 analysts have issued twelve-month target prices for Haemonetics' stock. Their HAE share price targets range from $88.00 to $115.00. On average, they expect the company's stock price to reach $103.40 in the next twelve months. This suggests a possible upside of 22.7% from the stock's current price. View analysts price targets for HAE or view top-rated stocks among Wall Street analysts. How have HAE shares performed in 2023? Haemonetics' stock was trading at $78.65 at the beginning of the year. Since then, HAE shares have increased by 7.1% and is now trading at $84.26. View the best growth stocks for 2023 here. Are investors shorting Haemonetics? Haemonetics saw a increase in short interest in the month of November. As of November 15th, there was short interest totaling 1,800,000 shares, an increase of 7.1% from the October 31st total of 1,680,000 shares. Based on an average daily trading volume, of 276,000 shares, the days-to-cover ratio is presently 6.5 days. Currently, 3.6% of the shares of the company are short sold. View Haemonetics' Short Interest. When is Haemonetics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, February 6th 2024. View our HAE earnings forecast. How were Haemonetics' earnings last quarter? Haemonetics Co. (NYSE:HAE) posted its quarterly earnings results on Thursday, November, 2nd. The medical instruments supplier reported $0.99 earnings per share for the quarter, beating the consensus estimate of $0.94 by $0.05. The medical instruments supplier had revenue of $318.18 million for the quarter, compared to the consensus estimate of $319.18 million. Haemonetics had a net margin of 10.35% and a trailing twelve-month return on equity of 22.33%. What ETFs hold Haemonetics' stock? ETFs with the largest weight of Haemonetics (NYSE:HAE) stock in their portfolio include SPDR S&P Health Care Equipment ETF (XHE), Invesco S&P MidCap Momentum ETF (XMMO), Invesco Dorsey Wright Healthcare Momentum ETF (PTH), Harbor Health Care ETF (MEDI) and Cultivar ETF (CVAR).iShares Russell 2000 Growth ETF (IWO). What is Christopher Simon's approval rating as Haemonetics' CEO? 48 employees have rated Haemonetics Chief Executive Officer Christopher Simon on Glassdoor.com. Christopher Simon has an approval rating of 63% among the company's employees. This puts Christopher Simon in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Haemonetics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Haemonetics investors own include NVIDIA (NVDA), Micron Technology (MU), Johnson & Johnson (JNJ), AbbVie (ABBV), Citigroup (C), Align Technology (ALGN), Chipotle Mexican Grill (CMG), Netflix (NFLX) and Pfizer (PFE). Who are Haemonetics' major shareholders? Haemonetics' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Wellington Management Group LLP (6.24%), FMR LLC (3.19%), Schroder Investment Management Group (1.52%), Boston Partners (1.44%), Boston Trust Walden Corp (1.42%) and Northern Trust Corp (1.26%). Insiders that own company stock include Anila Lingamneni, Christopher Simon, Dan Goldstein, Jacqueline Scanlan, Josep Llorens, Laurie A Miller, Mark W Kroll, Mark W Kroll, Michelle L Basil, Michelle L Basil, Richard J Meelia, Stewart W Strong and William P Mr Burke. View institutional ownership trends. How do I buy shares of Haemonetics? Shares of HAE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. This page (NYSE:HAE) was last updated on 12/3/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Haemonetics Co. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.